Life Foam™, an expanding, internal-use injectable hemostat, designed by gel-e Inc., has received a breakthrough status designation from the FDA.
Life Foam provides rapid, temporary control of bleeding from non-compressible abdominal wounds that do not lend themselves to tourniquet application during trauma and battlefield conditions. The product is designed to save the lives of those injured in battle, or who are victims of traumatic accidents or terrorist attacks.
Trauma from accidents is the third leading cause of death in the U.S. after heart disease and cancer. Approximately 85% of all hemorrhage-related deaths arise from non-compressible internal bleeding––intracavitary (e.g., abdominal) bleeding that is not accessible to direct pressure and cannot be controlled by typical methods such as gauze or a tourniquet.
When it is delivered into the abdominal cavity, Life Foam expands dramatically, seeking out the bleeding source in the patient for quick and efficient stabilization. This enables the injured person to be safely transported to a trained trauma surgeon, who can repair the damage in a controlled surgical environment.
The foam is currently in preclinical development for treating patients who have been injured in battlefield conditions or where life-threatening internal bleeding occurs in a location away from immediate urgent care.
Source: BioSpace, June 18, 2019